BREXAFEMME
ibrexafungerp Small Molecule Target: glucan synthase
Scynexis
Most recent annual filing: 2026-03-04
- BREXAFEMME filing2026BREXAFEMME filing, 2026, notable
- SCY-770 Ph2 start4Q 2026SCY-770 Ph2 start, 4Q 2026, notable
- SCY-770 Ph2 topline2H 2027SCY-770 Ph2 topline, 2H 2027, thesis-defining
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (5 active programs)
Technology platforms
fungerps
Proprietary antifungal platform comprising a novel class of triterpenoid glucan synthase inhibitors with broad-spectrum activity against Candida, Aspergillus, Pneumocystis, Coccidioides, Histoplasma, Blastomyces genera and mucorales species, including multidrug-resistant strains; focus on difficult-to-treat and drug-resistant fungal infections.
Targets: glucan synthase
fungerps · GSK
Proprietary antifungal platform based on triterpenoid (fungerp) chemistry; includes approved ibrexafungerp (BREXAFEMME) and pipeline candidate SCY-247; focus on treatment and prevention of invasive fungal infections
Biotech Distilled coverage (4)
- 2026-09-29 UPDATE: Scynexis (SCYX) - BARDA Funds the Antifungal 🔒 Paid
- 2026-08-13 UPDATE: Scynexis (SCYX) - Adage Shows Up 🔒 Paid
- 2026-08-11 UPDATE: Scynexis (SCYX) - The Negative Enterprise Value Just Evaporated 🔒 Paid
- 2026-06-24 Scynexis, Inc. (SCYX) - Scientific Deep Dive for SCY-770 (ADPKD) and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.